MX9305843A - Acidos bencenalcanoicos para enfermedades cardiovasculares. - Google Patents

Acidos bencenalcanoicos para enfermedades cardiovasculares.

Info

Publication number
MX9305843A
MX9305843A MX9305843A MX9305843A MX9305843A MX 9305843 A MX9305843 A MX 9305843A MX 9305843 A MX9305843 A MX 9305843A MX 9305843 A MX9305843 A MX 9305843A MX 9305843 A MX9305843 A MX 9305843A
Authority
MX
Mexico
Prior art keywords
pct
alkyl
date mar
benzenalcanoic
acids
Prior art date
Application number
MX9305843A
Other languages
English (en)
Inventor
Roger Peter Dickinson
Kevin Neil Dack
John Steele
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of MX9305843A publication Critical patent/MX9305843A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos de la fórmula: (Ver Fórmula I); en donde R1, R2, R3 y R4son cada H o alquilo de 1 a 4 átomos de carbono; R5 es (CH2)mNHSO2R6 o(CH)mNHCOR6; R6 es alquilo de 1 a 6 átomos de carbono, cicloalquilo de 3 a6 átomos de carbono, opcionalmente sustituido con arilo, arilo oheteroarilo R7 es H, alquilo de 1 a 4 átomos de carbono, alcoxi de 1 a 4átomos de carbono, halógeno, CF3, OCF3, CN, CONH2 o S(O)n (alquilo de 1 a4 átomos de carbono; X es CH2, CHCH3, CH(OH), C(OH)CH3, C=CH2, CO u O; mes O o 1 y n es O, 1 o 2; y sus sales farmacéuticamente aceptables y susésteres biclábiles, son antagonistas del tromboxano A2, y tienen utilidad,particularmente en combinación con un inhibidor de tromboxano-sintetasa,en el tratamiento de la ateroesclerosis y angina inestable, y para laprevención de la reoclusión después de una angioplastia transluminalpercutánea.
MX9305843A 1992-09-23 1993-09-22 Acidos bencenalcanoicos para enfermedades cardiovasculares. MX9305843A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929220137A GB9220137D0 (en) 1992-09-23 1992-09-23 Therapeutic agents

Publications (1)

Publication Number Publication Date
MX9305843A true MX9305843A (es) 1995-01-31

Family

ID=10722399

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9305843A MX9305843A (es) 1992-09-23 1993-09-22 Acidos bencenalcanoicos para enfermedades cardiovasculares.

Country Status (29)

Country Link
US (1) US5618941A (es)
EP (1) EP0662950B1 (es)
JP (1) JP2625262B2 (es)
KR (1) KR0169182B1 (es)
CN (1) CN1037176C (es)
AT (1) ATE162184T1 (es)
AU (1) AU666976B2 (es)
BR (1) BR9307091A (es)
CA (1) CA2145296C (es)
CZ (1) CZ72095A3 (es)
DE (1) DE69316380T2 (es)
DK (1) DK0662950T3 (es)
EG (1) EG20285A (es)
ES (1) ES2111176T3 (es)
FI (1) FI114862B (es)
GB (1) GB9220137D0 (es)
GR (1) GR3025909T3 (es)
HU (1) HUT70512A (es)
IL (1) IL106993A (es)
MX (1) MX9305843A (es)
MY (1) MY109576A (es)
NO (1) NO302698B1 (es)
NZ (1) NZ255412A (es)
PL (1) PL174431B1 (es)
RU (1) RU2110512C1 (es)
TW (1) TW283704B (es)
WO (1) WO1994006761A1 (es)
YU (1) YU60993A (es)
ZA (1) ZA936961B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4557397A (en) 1996-09-26 1998-04-17 Novartis Ag Aryl-substituted acrylamides with leukotriene b4 (ltb-4) receptor antagonist activity
US5986136A (en) * 1997-04-15 1999-11-16 President And Fellows Of Harvard College Photolabeling reagent
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
FR2827280B1 (fr) * 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003244913A1 (en) * 2002-07-09 2004-01-23 B.M.R.A. Corporation B.V. Pharmaceutical combination of a thromboxane A2 receptor antagonist and a COX-2 inhibitor
CN1318507C (zh) * 2003-03-04 2007-05-30 陈少岳 一种水晶树脂及其生产方法
CA2534316A1 (en) * 2003-08-07 2005-02-24 B.M.R.A. Corporation B.V. Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxygenase-1
DE102004007358B4 (de) * 2004-02-16 2017-10-12 Chiron As Kongenere, chlorierte, bromierte und/oder iodierte, fluorierte aromatische Verbindungen mit zwei Benzolringen in ihrer Grundstruktur, Verfahren zu ihrer Herstellung und ihre Verwendung
CN101160285A (zh) * 2005-03-17 2008-04-09 辉瑞大药厂 适用于治疗疼痛的n-(n-磺酰氨基甲基)环丙烷甲酰胺衍生物
GB0606201D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Improved crytalline material
US8551489B2 (en) 2008-01-03 2013-10-08 Musc Foundation For Research Development Methods for the treatment of cancers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3000377A1 (de) * 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
IL83230A (en) * 1986-08-06 1992-06-21 Tanabe Seiyaku Co Phenoxyacetic acid derivatives,their preparation and pharmaceutical compositions containing them
EP0325245B1 (en) * 1988-01-19 1993-10-20 Tanabe Seiyaku Co., Ltd. Phenoxyacetic acid derivatives, preparation thereof, pharmaceutical compositions comprising them and use
DE3819052A1 (de) * 1988-06-04 1989-12-07 Basf Ag Neue sulfonamid-derivate, ihre herstellung und verwendung
GB9107043D0 (en) * 1991-04-04 1991-05-22 Pfizer Ltd Therapeutic agents
TW219358B (es) * 1991-12-20 1994-01-21 Hokuriku Pharmaceutical

Also Published As

Publication number Publication date
PL174431B1 (pl) 1998-07-31
FI114862B (fi) 2005-01-14
EP0662950B1 (en) 1998-01-14
GR3025909T3 (en) 1998-04-30
KR0169182B1 (ko) 1999-03-20
TW283704B (es) 1996-08-21
DE69316380T2 (de) 1998-04-30
CN1087080A (zh) 1994-05-25
HU9500838D0 (en) 1995-05-29
MY109576A (en) 1997-02-28
PL308144A1 (en) 1995-07-24
KR950704242A (ko) 1995-11-17
AU4960093A (en) 1994-04-12
GB9220137D0 (en) 1992-11-04
CA2145296C (en) 2002-01-29
NO951080D0 (no) 1995-03-21
IL106993A (en) 1997-06-10
RU95108547A (ru) 1997-02-10
JPH08502046A (ja) 1996-03-05
CZ72095A3 (en) 1995-07-12
NO951080L (no) 1995-03-21
CA2145296A1 (en) 1994-03-31
CN1037176C (zh) 1998-01-28
NO302698B1 (no) 1998-04-14
EG20285A (en) 1998-07-30
NZ255412A (en) 1996-09-25
FI951341A (fi) 1995-03-22
IL106993A0 (en) 1993-12-28
RU2110512C1 (ru) 1998-05-10
US5618941A (en) 1997-04-08
AU666976B2 (en) 1996-02-29
ES2111176T3 (es) 1998-03-01
FI951341A0 (fi) 1995-03-22
JP2625262B2 (ja) 1997-07-02
WO1994006761A1 (en) 1994-03-31
DK0662950T3 (da) 1998-02-09
HUT70512A (en) 1995-10-30
BR9307091A (pt) 1999-03-30
ATE162184T1 (de) 1998-01-15
DE69316380D1 (de) 1998-02-19
EP0662950A1 (en) 1995-07-19
YU60993A (sh) 1997-07-31
ZA936961B (en) 1995-03-22

Similar Documents

Publication Publication Date Title
TW358096B (en) Pyrazolopyridimidinone antianginal agents
CA2044748A1 (en) Pyrazolopyrimidinone antianginal agents
FI950889A (fi) Antianginaaliset pyridopyrimidinoniaineet
ES2111176T3 (es) Acidos bencenoalcanoicos para enfermedades cardiovasculares.
CA2122360A1 (en) Quinazolinone Antianginal Agents
NZ331613A (en) Piperazinyl or piperidinyl substituted 1,2,3,4-tetrahydronaphthalene derivatives
DK0691951T3 (da) Fremgangsmåde til fremstilling af beta-phenylisoserinderivater
BR0208823A (pt) Composto, método de tratamento de distúrbios que são remediados ou aliviados pela atividade de agonista de vasopressina em um mamìfero necessitando do mesmo, e, composição farmacêutica
CO4750819A1 (es) Procedimientos para inhibir el inhibidor del activador del plasminogeno 1
ATE158301T1 (de) 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
ATE188695T1 (de) Indolderivate als 5-alpha-reductase-1 inhibitoren
AP2001002356A0 (en) Tricyclic analgesics.
MY155266A (en) Selective thrombin inhibitors